{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Lasa Supergeneri Reports Flat Performance in Q1 FY25, Achieves Highest Net Sales in 5 Quarters
Lasa Supergeneri, a microcap pharmaceutical company, has reported a flat performance for the quarter ended Jun 2024 with a slight improvement in its overall score. The company achieved its highest net sales in the last five quarters, but its PBT has fallen by 280.58% year on year. MarketsMOJO has given a 'Sell' call for the company's stock.
Lasa Supergeneri Reports Mixed Financial Results for Q1 FY25
MarketsMOJO has given a 'Sell' call for the company's stock.
Lasa Supergenerics Stock Hits 52-Week Low, Given 'Strong Sell' Rating by MarketsMOJO
Lasa Supergenerics, a microcap pharmaceutical company, has recently hit a 52-week low on June 5th, 2024, with a 'Strong Sell' rating from MarketsMOJO. The stock has underperformed the sector by -4.83% and is trading below its moving averages. In the past year, it has seen a -20.56% performance compared to Sensex's 15.55%. Investors should carefully consider their options and do their own research before making any decisions.
Lasa Supergenerics Reports Significant Decline in Financial Performance for Q1 2024
Lasa Supergenerics, a microcap pharmaceutical company, has reported a significant decline in its financial performance for the quarter ending March 2024. This is mainly due to a decrease in net sales and a sharp decline in profit before and after tax. The company's stock has been given a 'Strong Sell' call by MarketsMOJO.
Lasa Supergenerics Reports Negative Performance in Q4, Receives 'Strong Sell' Rating
Lasa Supergenerics, a microcap pharmaceutical company, has reported a negative performance in the quarter ending December 2023, with a score of -6. This is due to a decline in net sales and profit after tax. MarketsMOJO has given a 'Strong Sell' rating for the company's stock based on these financial results.
Lasa Supergenerics' Stock Hits 52-Week High, Outperforms Sensex in Past Year
Lasa Supergenerics, a microcap pharmaceutical company, saw its stock price reach a 52-week high of Rs. 40.95 on January 9, 2024. Despite this, the stock is currently rated as a 'Sell' by MarketsMOJO and underperformed the sector by -5.42% today. The stock has been highly volatile but is trading above its moving averages and has outperformed the Sensex in the past year. Investors should carefully consider all factors before making any investment decisions.
Lasa Supergenerics Outperforms Sector and Sensex, Stock Rises by 37.08%
Lasa Supergenerics, a microcap pharmaceutical company listed on the Indian stock exchange, has seen a significant increase in its stock price, outperforming the sector by 10.07%. In the last 5 days, the stock has risen by 37.08% and is currently trading higher than its moving averages. While MarketsMOJO suggests selling, the recent performance has caught the attention of investors.
Lasa Supergenerics' Stock Soars, Outperforming Sector and Sensex
Lasa Supergenerics, a microcap pharmaceutical company listed on the Indian stock exchange, has shown a significant improvement in its stock performance. It has outperformed the sector by 9.52% and is currently trading higher than its moving averages. Despite a 'Sell' call from MarketsMOJO, investors should do their own research on this promising company.
Lasa Supergenerics' stock surges 25.17% in 4 days, outperforming sector and Sensex
Lasa Supergenerics, a microcap pharmaceutical company listed on the Indian stock exchange, has seen a 25.17% increase in its stock value in the past 4 days. Today, the stock opened with a gain of 5.57% and hit a new 52-week high. Despite positive indicators, MarketsMOJO has given a 'Sell' call for the stock.
Lasa Supergenerics Reports Mixed Financial Performance
Lasa Supergenerics, a microcap pharmaceutical company, has reported a decline in net sales and profit in the quarter ended September 2023. However, the company's EPS has increased, indicating higher profitability for shareholders. Investors should carefully consider the company's financial performance before making any investment decisions.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}